5 Stories in coverage 11 approved Program 52 recruiting Registered trials 8-K Aug 12 Latest SEC filing, period to Aug 11 Sep 29 Latest story
Timeline 5 Pipeline 1 Trials 5
All5 Trials and readouts3 Filings and people2
Pipeline by stage
Approved 1
Phase 3 primary completions, next 6 months
All trials by completion date Details
Headquarters West Conshohocken, PA Incorporated Delaware Industry Pharmaceutical Preparations Formerly MADRIGAL PHARMACEUTICALS, INC. (to 2026); SYNTA PHARMACEUTICALS CORP (to 2016) Also known as MDGL How the company describes itself Madrigal Pharmaceuticals develops Rezdiffra (resmetirom), an oral THR-β agonist for metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. The company is evaluating Rezdiffra in Phase 3 for compensated MASH cirrhosis. source
